Display options
Cite
Toda H, Kawazoe H, Yano A, et al. Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy. J Cancer. 2017;8(8):1371-1377doi: 10.7150/jca.17102.
Toda, H., Kawazoe, H., Yano, A., Yamamoto, Y., Watanabe, Y., Yamamoto, Y., Hiasa, Y., Yakushijin, Y., Tanaka, A., & Araki, H. (2017). Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy. Journal of Cancer, 8(8), 1371-1377. https://doi.org/10.7150/jca.17102
Toda, Haruka, et al. "Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy." Journal of Cancer vol. 8,8 (2017): 1371-1377. doi: https://doi.org/10.7150/jca.17102
Toda H, Kawazoe H, Yano A, Yamamoto Y, Watanabe Y, Yamamoto Y, Hiasa Y, Yakushijin Y, Tanaka A, Araki H. Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy. J Cancer. 2017 May 12;8(8):1371-1377. doi: 10.7150/jca.17102. eCollection 2017. PMID: 28638451; PMCID: PMC5479242.
Copy Download .nbib Format: NLM
Share it on

J Cancer. 2017 May 12;8(8):1371-1377. doi: 10.7150/jca.17102. eCollection 2017.

Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy.

Journal of Cancer

Haruka Toda, Hitoshi Kawazoe, Akiko Yano, Yuji Yamamoto, Yuji Watanabe, Yasunori Yamamoto, Yoichi Hiasa, Yoshihiro Yakushijin, Akihiro Tanaka, Hiroaki Araki

Affiliations

  1. Division of Pharmacy, Ehime University Hospital, Shitsukawa, Toon, Ehime 791-0295, Japan.
  2. Division of Gastrointestinal Surgery and Surgical Oncology, Department of Surgery, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan.
  3. Endoscopy Center, Ehime University Hospital, Shitsukawa, Toon, Ehime 791-0295, Japan.
  4. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan.
  5. Cancer Center, Ehime University Hospital, Shitsukawa, Toon, Ehime 791-0295, Japan.

PMID: 28638451 PMCID: PMC5479242 DOI: 10.7150/jca.17102

[No abstract available.]

Keywords: aprepitant; cost-saving.; gastrointestinal cancer; moderately emetogenic chemotherapy; palonosetron

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

References

  1. J Clin Oncol. 2013 Dec 10;31(35):4438-44 - PubMed
  2. Ann Oncol. 2015 Jan;26(1):141-8 - PubMed
  3. Lancet Oncol. 2010 Sep;11(9):853-60 - PubMed
  4. J Clin Oncol. 2008 Apr 20;26(12):2006-12 - PubMed
  5. Ann Oncol. 2016 Aug;27(8):1601-6 - PubMed
  6. Int J Clin Oncol. 2016 Feb;21(1):1-12 - PubMed
  7. Lancet Oncol. 2009 Feb;10(2):115-24 - PubMed
  8. J Clin Oncol. 2014 Oct 20;32(30):3413-20 - PubMed
  9. Eur J Cancer. 2015 Jul;51(10):1274-82 - PubMed
  10. Cancer Sci. 2013 Jun;104(6):711-7 - PubMed
  11. J Clin Oncol. 2016 Feb 1;34(4):381-6 - PubMed
  12. Int J Clin Oncol. 2015 Oct;20(5):855-65 - PubMed

Publication Types